Amylyx (AMLX) CFO James Frates Sells Shares

What Happened

• James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals (AMLX), reported sales of company stock on 2026-09-10. He sold 9,768 shares at a weighted-average price of $32.27 (proceeds $315,195) and 1,042 shares at a weighted-average price of $33.23 (proceeds $34,626), for a total of 10,810 shares and approximately $349,821.
• These sales were automatic dispositions to satisfy tax-withholding obligations in connection with the vesting of performance stock units (footnote F1), not discretionary open-market trades.

Key Details

• Transaction date: 2026-09-10; Form 4 filed 2026-09-14 (timely filed under Section 16 rules).
• Reported prices: weighted averages $32.27 and $33.23. Footnotes note the sales occurred in multiple trades at price ranges of $31.805–$32.71 (F2) and $32.84–$33.45 (F3).
• Total shares sold: 10,810; total proceeds: ~$349,821.
• Reason: Tax withholding on vested performance stock units (automatic; footnote F1). Transaction code shown as S (sale) and withholding-related code F.
• Ownership after transaction: not disclosed in the provided excerpt.
• Additional footnotes (F4–F7) state certain shares are held in trusts for which Mr. Frates is trustee and disclaim beneficial ownership for Section 16 purposes.

Context

• These sales are routine tax-withholding transactions tied to vesting and do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases by insiders tend to be more informative about confidence, while mandatory withholding sales are common and administrative in nature.